The objective of this comprehensive analysis is to evaluate and compare the efficacy, safety, and long-term outcomes of SGLT2 inhibitors, DPP-4 inhibitors, metformin, and insulin in the management of T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.